← Back to Search

Myosin Inhibitor

Aficamten for Pediatric Hypertrophic Cardiomyopathy (CEDAR-HCM Trial)

Phase 2 & 3
Recruiting
Research Sponsored by Cytokinetics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Body weight ≥ 45 kg for the initial cohort and then body weight ≥ 35 kg after at least 10 participants in the initial cohort have undergone dose titration up to Week 4 without observed events of LVEF < 50% at the starting dose of 5 mg qd
New York Heart Association (NYHA) Class ≥ II at screening
Must not have
History or evidence of any other clinically significant disorder, malignancy, active infection, or condition that would pose a risk to participant safety or interfere with the trial
Implantable cardioverter defibrillator (ICD) implantation within 6 weeks of screening or planned ICD implantation during the trial period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 8 or week 12
Awards & highlights

Summary

"This trial aims to see how well aficamten works, how safe it is, and how the body processes it in children with a type of heart condition called obstructive hypertrophic cardiomyopathy

Who is the study for?
This trial is for young people aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). They must have a certain level of heart function and obstruction, be in NYHA Class II or higher, and on stable doses of specific heart medications. Genetic testing should confirm oHCM or assume it if no other conditions are present. Participants need to weigh at least 35 kg after the initial cohort.
What is being tested?
The study tests Aficamten's effectiveness, safety, and pharmacokinetics (how the drug moves through the body) in pediatric patients with oHCM. It compares Aficamten against a placebo – an inactive substance designed to test if the real drug works.
What are the potential side effects?
While not specified here, side effects may include those common to heart medications such as dizziness, low blood pressure, changes in heartbeat rhythm or rate; however individual experiences can vary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My weight is at least 45 kg, or 35 kg after the first 10 participants.
Select...
My heart condition limits my physical activity.
Select...
I am between 12 and 17 years old.
Select...
My heart's muscle is thickened, and tests show specific heart function and pressure levels.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I don't have any other serious health issues that could affect my safety in the trial.
Select...
I have had or will have an ICD implant within 6 weeks of screening or during the trial.
Select...
I have previously taken aficamten or mavacamten.
Select...
I do not have serious heart valve problems.
Select...
I have a history of weak heart muscle or stress-related heart condition.
Select...
I am undergoing or planning to undergo stereotactic radiotherapy.
Select...
I have a history of heart rhythm problems.
Select...
I have used drugs that can affect heart muscle.
Select...
My heart's pumping ability is below 40%, causing a treatment pause.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 8 or week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 8 or week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Maximum observed concentration (Cmax) of aficamten

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AficamtenExperimental Treatment1 Intervention
Participants in this arm will receive a single daily oral dose of aficamten with dose levels (5 mg to 20 mg) guided by echocardiography assessments, for 12 weeks during the double-blinded period, and then for another 52 weeks during the open-label extension period.
Group II: PlaceboPlacebo Group2 Interventions
Participants in this arm will receive placebo for 12 weeks during the double-blinded period, and then will receive aficamten for 52 weeks during the open-label extension period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aficamten
2023
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

CytokineticsLead Sponsor
41 Previous Clinical Trials
15,607 Total Patients Enrolled
Cytokinetics MDStudy DirectorCytokinetics
3 Previous Clinical Trials
773 Total Patients Enrolled
~27 spots leftby Dec 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top